WHEN IT COMES TO HER2NEU TESTING, a study of accuracy just published by the journal Cancer may raise interesting questions for pathology groups across the nation.
“Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2- negative breast cancer,” was the title of the study published by Cancer on June
CEO SUMMARY: As the closing year of the first decade of the new century and the new millennium, 2009 brought neither disruption nor upheaval to the majority of laboratories in the United States. Rather, it was marked by at least two themes. One was how public disclosure of problems with lab testing services generated media
CEO SUMMARY: Every second year, THE DARK REPORT releases its list of key trends in anatomic pathology. These trends help shape an understanding about the state of the pathology profession. Our current list includes 11 identifiable trends. This is not an auspicious sign for pathologists who prefer things to remain the same. Eleven distinct trends
IF THE NEW BUSINESS AGREEMENT between Ventana Medical Systems, Inc. and TriPath Imaging, Inc. is successful, then the anatomic pathology laboratory may have a very different look in future years.
Last week, Ventana Medical Systems, Inc. announced a five-year global supply agreement with TriPath Imaging, Inc. that involves two primary objectives. First, Ventana will put its
QUEST DOES DEAL WITH CVS DRUGSTORES FOR LAB TESTING
PATHOLOGISTS CONCERNED about pharmacists moving into the lab testing arena should closely watch the newly-announced relationship between Quest Diagnostics Incorporated and CVS Corporation.
Starting this month, CVS pharmacies in Columbus, Ohio and Tampa/St. Petersburg, Florida now sell lab tests. Participating pharmacies have a card display for 12 different